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Abstract
Background: In recent years, the management of synchronous colorectal liver metastasis has 
changed significantly. Alternative surgical strategies to the classical colorectal-first approach 
have been proposed. These include the liver-first and combined resections approaches. The 
objectives of this review were to compare the short and long-term outcomes for all three 
approaches.
Methods: A systematic review of comparative studies was performed. Evaluated endpoints
included surgical outcomes(5-year overall survival, 30-day mortality, and post-operative 
complications). Pair-wise and network meta-analysis(NMA) were performed to compare survival 
outcomes.
Results: 18 studies were included in this review, reporting on 3,605 patients. NMA and pair-
wise meta-analysis of the 5-year overall survival did not show significant difference between the 
three surgical approaches: combined vs. colorectal-first, mean odds- ratio 1.02(95% CI 0.8-1.28,
p=0.93); liver-first vs. colorectal-first, mean odds-ratio 0.81(95% CI 0.53-1.26, p=0.37); liver-
first vs. combined, mean odds-ratio 0.80(95% CI 0.52-1.24, p=0.41). In addition NMA of the 30-
day mortality among the three approaches also did not observe statistical difference. Analysis of 
variance showed that mean post-operative complications of all approaches were 
comparable(p=0.51).
Conclusion: There are considerable differences in the peri-operative management of 
synchronous CLM patients. This meta-analysis demonstrated no clear statistical surgical 
outcome or survival advantage towards any of the three approaches.  
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Introduction
Colorectal cancer is the second most common cause of cancer-related deaths in the United States
and in the United Kingdom. [1-2] The most common metastatic site is the liver,[3] with 15-25% 
of patients having colorectal liver metastasis (CLM) at the time of diagnosis,[4-5] and another 
30-50% of patients developing CLM during their treatment course.[5-7] The presence of CLM is 
a poor prognostic factor conferring a median survival of 6-12 months in untreated patients. [8] A
complete surgical resection is considered the best chance for long term survival, however 
unfortunately only 20% of patients with CLM are eligible for radical resection. [9-10] Recently, 
with advances in chemotherapy regiments and liver-directed therapy, as well as with the 
improvement of operative techniques, the 5-year survival of patients who underwent surgical 
resection for CLM has risen to 40-58%.[11-13]
The optimal surgical management of patients with colorectal cancer and synchronous liver 
metastasis is still controversial. Traditionally, colorectal cancer patients with synchronous liver 
metastasis would undergo a staged approach,[14] consisting of the resection of the primary 
tumor followed by hepatectomy at a later date (colorectal-first approach). The rationale is that 
the primary neoplasm should be managed first because it is both the source of further metastasis 
and potential complications, including intestinal obstruction, perforation or massive 
gastrointestinal bleeds.[15] The staged approach also provides the opportunity for recovery after
the initial surgery and for commencing chemotherapy earlier. In addition, this approach enables a
“natural selection” of patients. Those with “less favorable” disease typically have either 
progression of metastasis or significant morbidities after their primary surgery, and therefore are 
deemed unsuitable for hepatic resection. [16] More recently, in order to prevent delays in liver-
directed therapy or in systemic treatment, some authors have advocated the liver-first approach.
[15]
Alternatively, when technically feasible and clinical applicable, some centers have shifted to a
combined approach. The potential benefit of performing a combined resection of both the 
primary colorectal and the liver metastatic tumor includes a single operation and anesthetic
induction with an overall reduction in the total hospital length of stay.[1,17] In contrast, this 
approach may increase the complexity of the surgical procedure and the length of the operation, 
raising concern on safety and the long-term outcomes.[1,5]
4 
 
Several studies have compared the different surgical approaches in an effort to identify whether 
one confers a survival advantage over the others, but the evidence so far has been inconclusive.
[18-21] In this context, we sought to systematically review the existing evidence relating to 
clinical outcomes of patients with synchronous CLM depending on the surgical approach, and 
synthesize the data using the methodology of meta-analysis.
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Methods
A systematic review was performed according to the guidelines and recommendations from the 
preferred reporting items for systematic reviews and meta-analyses checklist (PRISMA). [22]
Institutional review board approval was not required.
Search strategy
An electronic search for relevant publications was performed using the following resources:
PubMed, Embase, Ovid and the Cochrane collaboration database from January 1998 to 
November 2013. The following search headings were used: “colorectal liver metastasis surgery”,
“resectable synchronous colorectal liver metastasis”, “synchronous colorectal liver metastasis 
surgery”, “liver first approach surgery synchronous colorectal liver metastasis”, “staged surgery 
synchronous colorectal liver metastasis”, and “combined surgery synchronous colorectal liver 
metastasis”. Subsequently, we repeated the search on PubMed using the following medical 
subject headings (MeSH); “surgical procedures, operative” AND “colorectal neoplasm” AND 
“neoplasm, synchronous”. All titles were initially screened and appropriate abstracts were
reviewed. Each of the relevant publication reference section and Google scholar was also 
screened for other applicable publications. The last date of search was November 12th, 2013. 
Inclusion criteria
To be included in the analysis, the studies had to meet the following criteria: a) report on patients 
with synchronous colorectal liver metastasis (CLM); b) compare the approaches for synchronous 
CLM (either colorectal-first approach vs. combined, combined vs. liver-first approach or 
compare all three approaches); c) report on surgical and outcomes measures mentioned below; d)
have a clear research methodology; e) have the longest follow-up or the largest sample size when 
two or more studies were reported by the same institution.
Exclusion criteria
Studies were excluded from the analysis if: a) they did not specify that CLM were synchronous 
to primary disease; b) they did not compare the surgical approaches; c) outcomes of interest were 
not reported; d) the methodology was not clearly reported; e) the data were overlapping among 
authors; f) the patients in the studies had a planned two stage hepatectomy or hybrid approach to 
define the CLM diagnosis.
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Data extraction
Two reviewers (MK, GS) independently reviewed the literature according to the above
predefined strategy and criteria. Each reviewer extracted the following data variables: title and 
reference details (first author, journal, year, country), study population characteristics (number in 
study, number treated by each approach, gender and age), disease characteristics (location of the 
primary lesion, location of hepatic metastasis, number and size of CLM), type and approach of 
surgical intervention, and outcome data. All data were recorded independently by both literature 
reviewers in separate databases and were compared at the end of the reviewing process to limit
selection bias. The database was also reviewed by a third person (DW). Duplicates were 
removed and any disparities were clarified. 
Outcomes of interest
The following outcomes were used in the meta-analysis to compare the three approaches in 
management of synchronous CLM:
Primary outcome:
1. Survival outcome: 5-year overall survival
Secondary outcome:
2. Surgical outcomes: Post-operative complications and 30-day mortality
Other areas of interest, but not included in the meta-analysis were: length of hospital stay, 
duration of surgery, volume of blood loss and transfusion requirements. 
Statistical analysis
Descriptive statistic was used to report the characteristics of all eligible trials, describing the 
types of surgical modalities, total patients numbers, mean age, duration of surgery, amount of 
blood loss, and median length of stay.
Statistical analysis was conducted using STATA software (Version 13, StataCorp LP, USA).
Analysis of dichotomous variables was performed using odds ratio (OR), reported with 95% 
confidence interval (CI). First, we utilized pair-wise meta-analysis to compare the overall 5-year 
survival between the three surgical approaches, using the random-effects model with the 
assumption that there is a variation between studies. The test for heterogeneity was investigated 
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by visual inspection of the forest plots and I2 statistic, which provides the percentage of 
variability attributed to heterogeneity rather than sampling error. The odds-ratio (OR) was 
considered to be statistically significant at the p < 0.05 level if the 95% CI did not include the 
value of 1. 
Second, we performed a network meta-analysis (NMA) using STATA to compare the three 
surgical approaches simultaneously. NMA synthesizes data from a network of trials involving
multiple interventions and therefore has the potential to rank the treatments according to the 
studied outcome. [23] This method integrates direct and indirect comparisons of interventions.
In NMA, a common heterogeneity variance is assumed across all pair-wise comparisons. The 
NMA results are represented graphically in a forest plot with the mean odds-ratios together with 
their 95% confidence and predictive intervals. The predictive intervals provide an estimated 
interval within which the results of future studies are expected to be. Within the framework of 
NMA, we ranked the evaluated surgical interventions based on the mortality outcome. The 
surface under the cumulative ranking curve (SUCRA) was used to provide ranking probabilities. 
The larger the SUCRA value, the better the rank of the intervention. We also performed a 
network meta-regression accounting for small-study effects (using the variance of the log-odds 
ratios as covariate).[23] This was graphically represented together with the SUCRA. 
One-way analysis of variance (ANOVA) was used to analyze the differences between the mean 
numbers of complications of each surgical approach. The F-ratio was used as a test for the null 
hypothesis of equality of the means. A statistically significant result is denoted by p < 0.05. 
The quality of the studies included in this systematic review was assessed by the Newcastle-
Ottawa scale (NOS),[24] to evaluate patient selection methodology, comparability and 
assessments of outcomes. The quality score rating was determined for each publication, with 
eight or more stars representing studies of higher quality.
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Results
Eligible studies
A total of 1,929 articles were initially identified using the aforementioned search strategy. On 
full text screening, 18 publications that met the inclusion criteria were included in the meta-
analysis (Figure 1). All studies were retrospective, and were published between January 1998 
and November 2013. All studies were comparative, reporting on at least two surgical approaches 
for synchronous CLM. On review of the extracted data, there was 100% agreement between the 
two reviewers. Numbers, characteristics and quality of the studies assessed by the Newcastle-
Ottawa scale (NOS) are outlined in Table 1.
Demographics
Analysis was performed on 3,605 patients, of which 2,439 (67.7%) had classical colorectal-first 
resection, 133 (3.7%) had liver-first resection and 1,033 (28.6%) had combined resections. The 
studies spanned a mean time period of 14.3 years, with patients operated from 1982 to 2012 
(Table 1). Across all studies, male gender was more common, accounting for 58.9%, 60.1% and 
54.7% of all patients treated as colorectal-first, liver-first and combined approach respectively 
(Table 2).
Sixteen studies reported colorectal distribution of primary tumor. Colorectal first approach had 
71.2% (n=1696) colonic primaries and 23.8% (n=684) rectal primaries. Liver-first approach had 
less colonic primaries at 50.4% (n=57) and more rectal primaries at 49.6% (n=56). Combined 
approach had 67.8% (n=652) colonic primaries and 32.2% (n=309) rectal.
Fourteen studies reported hepatic distribution of CLM. The colorectal-first approach had 48.3% 
(n=1091) unilobar and 51.7% (n=1167) bilobar CLM. The liver-first approach had 33.9% (n=38) 
unilobar and 66.1% (n=74) bilobar CLM. The combined approach had 64.7% (n=623) unilobar 
and 35.3% (n=340) bilobar CLM. (Table 2)
Surgical outcomes
There was a considerable heterogeneity in the methods of reporting surgical outcomes and 
complications among the studies. Only 9 studies reported on the duration of surgery with no 
information pertaining to liver-first strategy. Seven studies reported the median blood loss, and 8
studies reported on blood transfusion requirements. Sixteen studies reported post-operative 
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complications, with only 7 actually specifying the types of complication. Ten studies reported on 
the length of stay, including only 1 study from liver-first strategy (Table 3).
Overall results of meta-analysis
Meta-analysis of 5-year overall survival (Primary outcome)
Fifteen studies reported on the 5-year overall survival (OS). However, only 3 studies compared 
the 5-year OS for all 3 approaches; while 11 studies included 5-year OS for combined vs. 
colorectal-first, and 1 study reported 5-year OS for colorectal-first vs. liver-first. Pair-wise meta-
analysis did not show significant difference between the three treatment approaches (p = 0.93 for 
combined vs. colorectal-first; p = 0.37 for liver-first vs. colorectal-first; p = 0.41 for liver-first vs.
combined) (Figure 2). There was significant heterogeneity amongst the studies involving the 
liver-first vs. colorectal-first approaches (p = 0.019, I2 = 69.8%). This significance was due to 
one study finding higher OS in the liver-first group. 
The finding of no significant difference between the 3 treatment approaches was concurred by 
the network meta-analysis. The forest plot depicting the estimated summary effects in the form 
of mean odds-ratios along with their confidence intervals and corresponding predictive intervals 
is presented in Figure 3. All confidence intervals crossed the line of no effect (combined vs. 
colorectal-first: mean odds- ratio 1.02 (95% CI 0.8-1.28); liver-first vs. colorectal-first: mean 
odds-ratio 0.81 (95% CI 0.53-1.26); liver-first vs. combined: mean odds-ratio 0.80 (95% CI 
0.52-1.24). Within the frame-work of this network meta-analysis, the SUCRA probability was 
highest for combined approach at 69.8%. However, when adjustment for small-study effects was
made, the liver-first approach was preferred at 78.9%. 
Meta-analysis of post-operative outcomes
Only 5 studies reported 30-day mortality for the different surgical approaches. Network meta-
analysis did not find significant difference amongst the three groups as all confidence intervals 
crossed the line of no effect (combined vs. colorectal-first: mean odds- ratio 1.26 (95% CI 0.53-
2.99); liver-first vs. colorectal-first: mean odds-ratio 0.56 (95% CI 0.03-11.22); liver-first vs. 
combined: mean odds-ratio 0.44 (95% CI 0.02-8.91) (Figure 4). 
Sixteen studies reported the post-operative complications. From ANOVA, there was no
difference found between the mean number of complication events of the three surgical 
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approaches (colorectal-first mean 37.4 (SD 19.0), combined mean 33.0 (SD 17.9), liver-first 
mean 22.1 (SD 21.1), p = 0.51). For the colorectal-first group, the complication rate was 29.3%
(n = 489), within which respiratory events (sepsis and pleural effusions, 12.2%, n=60), bile leak
(7.9%, n=39), and intra-abdominal collection/abscess (5.9%, n=29) were the most common. The 
complication rate of the combined group was 30.7% (n = 294) with the most common types of 
complications being intra-abdominal collection/abscess (9.8%, n=29), wound infection (7.8%, 
n=23) and respiratory sepsis/pleural effusions (6.8%, n=20). Comparison of high-quality studies 
126WRWKRVHRIORZHUTXDOLty (NOS < 8) yielded similar complication rates. For the 
colorectal-first group, eleven high-quality studies that reported complication events had an
overall rate of 27.8%, while the rate of the five low-quality studies was 31.1%. Similarly in the 
combined group, the complication rates for the high and low quality-studies were 30.6% and 
31.0%, respectively. As for the liver-first group, only 2 studies reported complications with an
overall rate of 16.5% (n = 12).
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Discussion
This systematic review and meta-analysis compared the three surgical approaches in the 
management of patients with synchronous colorectal liver metastasis, with a specific aim to 
assess which approach conferred the best chance for long term survival.  Despite the 
advancements in chemotherapy regimens and the use of biological agents, no treatment other 
than surgery has shown a survival plateau for the management of synchronous CLM. [25] There 
is clear evidence from randomized control trials that resection of hepatic metastasis has 
significant value in improving survival outcomes and quality of life with 5-year survival between 
25-40% post CLM resection in selected patients. [25,27,28] The timing of surgery for patients 
with synchronous CLM is currently a hot topic, since there is no consensus on the approach
strategy or contraindications to resection of CLM yet. Moreover, studies have observed that the 
potential for CLM resection is often under-estimated,[26] with many patients deemed 
unresectable too soon without being referred to specialized hepato-biliary centers.[1] This lack of 
consensus emphasizes the need for clear international guidelines and referral pathways to 
optimize long term clinical outcomes in patients with CLM.
Those in favor of the classical colorectal-first or delayed approach postulate that the interval 
between primary resection and CLM resection provides the opportunity to delineate those 
patients with unfavorable cancer biology, and therefore prevent them from undergoing major 
surgical resection with potential related morbidity.[10] In addition, there is the worry that 
delaying primary resection may increase the rate of complications from the primary including 
perforation, obstruction and bleeding. Studies have reported this rate as high as 20% but some 
argue that this may be over-stated.[29-30]
Alternatively, proponents of both combined or liver-first (reverse) strategies argued that the 
presence of synchronous CLM already indicates that the patients have poor cancer biology. 
Therefore it is reasonable that these patients should receive chemotherapy upfront, and then be 
reassessed to determine which surgical approach is appropriate if at all. Colorectal cancer is 
predominantly chemo-sensitive, and therefore early chemotherapy is logical. Lam et al. had
shown that neoadjuvant chemotherapy resulted in down-staging and conversion of unresectable 
disease in 22.5% of patients.[31] Centers that strongly favor this approach contend that a post-
immunodeficiency state occurs after primary resection which drives the rate of metastatic 
growth, and that chemo-therapy is typically delayed due to recovery from the primary 
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resection.[32-33] Advocates of combined resection assert that its greatest advantage is that 
patients receive one general anesthetic, and one operation. This approach offers reduction in total 
hospital length of stay, risk of morbidity and healthcare cost overall.[10, 19, 34] Liver-first 
(reverse strategy) is invariably a misleading term as patients undergo neoadjuvant treatment prior 
to surgical resection. This strategy does facilitate early control CLM by early hepatic resection 
hoping to optimize patient’s survival.[35] However, studies reporting on this treatment strategy 
have been highly selective, and therefore are not representative of the spectrum of synchronous 
CLM patients. Moreover, concerns over the adverse effects of neoadjuvant chemotherapy have 
been raised. Reports of liver changes including steatosis, non-alcoholic steatohepatitis, sinusoidal 
changes and centrilobular necrosis have been cited, potentially delaying surgery.[36] Despite 
these reports, recent studies had observed and speculated that bevacizumab may protect the liver 
from sinusoidal damage from chemotherapy agents such as oxaliplatin.[37]
Of note, there was a considerable heterogeneity in the 5-year overall survival rates reported for 
patients treated with the liver-first approach, ranging from 39% to 67% in this review. Many
surgeons consider that liver-first strategy is a highly selective strategy, which should be reserved
for patients with a high burden of CLM, but with low risk of the primary neoplasm causing 
complications.[38] Our review observed that liver-first patients had the highest number of 
bilobar disease at 66.1%, compared to that of the combined resection group at 35.3%. This was
expected as the rationale for the liver-first approach is to facilitate early control of CLM in the 
hope to offer patients down-staging therapy and curative resections. In addition, the colorectal-
first approach had substantially more colonic primaries (71.2%) whereas, the liver-first approach 
had an evenly distribution between colonic and rectal neoplasm (50.4% and 49.6% respectively).
This was likely due to a traditional emphasis for early resection of colonic neoplasm to prevent 
complication, whereas in recent years the role of neo-adjuvant therapy for rectal tumors had been 
strongly advocated. 
Though 15 studies reported on 5-year overall survival, only 3 studies compared all three surgical 
approaches. Broquet et al. were the first authors to retrospectively compare all three treatment 
strategies for management of synchronous CLM.[21] They found comparable surgical outcomes, 
morbidity and mortality between all three treatment approaches. In concordance, our systematic 
review and meta-analyses found no significant difference between those surgical approaches. 
Interestingly though, upon further analysis, our network meta-analysis surface under the 
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cumulative ranking curve showed a tendency towards better outcomes in patients treated with the
liver-first approach (78.9%) when adjusted for small-study effects. This finding could be 
attributed to the highly selective nature of the liver-first patient cohort and small sample size. We 
also noted that the combined surgical approach had a higher, though not statistically significant, 
rate of intra-abdominal collection/abscess most likely due to the fact that this approach evolves 
more extensive resection.
This study is the first systematic review and meta-analysis comparing all three surgical 
approaches for synchronous CLM, and as such it bears important clinical implications.
Unfortunately, due to non-availability of more detailed time-to-event data in the original studies, 
it was impossible to use the ideal method of survival meta-analysis to compare hazard ratios 
instead of odds ratios of 5-year survival; however standard meta-analysis has been routinely used 
for comparison of survival data when detailed time-to-event data are not available. Our review 
also highlighted several limitations to the current data available. Currently, there are no
randomized control trials comparing all three surgical approaches; instead, there are only limited 
retrospective studies that have mostly compared 2 surgical approaches. In addition, there remain 
vast differences in chemotherapy regimens, especially in relation to the role and use of biological 
agents. The evolution of surgical and anesthetic technology has added more variation over recent 
years. Current studies have considerable disparity in the age of patients, site of primary 
neoplasm, size, number and distribution of hepatic metastasis. All these aspects add substantial 
heterogeneity to the current data skewering any possible inference. Therefore, there is a need for 
prospective comparative trials (ideally randomized and including all three approaches) with 
standardized reporting of surgical outcomes including the length of surgery, blood transfusion 
and intensive care requirements, associated morbidities, length of hospital stay and both three 
and five-year disease free and overall survival to properly assess the superiority of one surgical 
approach over the others.
Nevertheless, our review and meta-analysis suggests that all surgical approaches have 
comparable outcomes. Therefore, the aim of surgical care could be to assess each case 
individually with multi-disciplinary input and select the appropriate approach available to each 
patient. Those patients with a high burden of liver disease may be more likely to benefit from 
early surgical intervention via liver-first approach, whereas the classical colorectal-first approach 
may be more appropriate for patients who do not require down-staging therapy.
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Conclusion
The management of colorectal cancer with synchronous CLM is evolving. The decision for 
timing of the primary and CLM resection should be individualized for each patient based on
technical, oncological and patient considerations, with multi-disciplinary team input. Our 
network meta-analysis showed no significant difference in the 5-year overall survival of the three 
surgical approaches. There is growing need for randomized controlled trials to further 
investigate differences in clinical outcomes of the 3 different approaches.
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Figure Legends:
Figure 1. PRISMA flow diagram demonstrating results of literature search.
Figure 2. Forest plots of pair-wise standard meta-analysis of the 3 surgical approaches. OR = 
odds ratio, CI = confidence interval
Figure 3. A) Network meta-analysis predictive interval plot for the 3 surgical approaches.  The 
black lines represent the confidence interval (CI) for mean odds-ratio (OR) for each comparison. 
The red lines are the predictive intervals (PrI). The blue line denotes the line of no effect (OR = 
1). B) Plots of the surface under the cumulative ranking curves (SUCRA) for 3 treatments. The 
table presents the SUCRA hierarchical values (in percentage) for each surgical approach. The 
graphs show that small-study effects alter the ranking of treatments putting liver-first as the most 
favorable approach. 
Figure 4. Network meta-analysis for 30-day mortality of the 3 surgical approaches. The black 
lines represent the confidence interval (CI) for mean odds-ratio (OR) for each comparison. The 
red lines are the predictive intervals (PrI). The blue line denotes the line of no effect (OR = 1).
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